Article
 

Nanostructured Lipid Carriers as Multifunctional Nanomedicine Platform for Pulmonary Co-Delivery of Anticancer Drugs and siRNA

Public Deposited

Downloadable Content

Download PDF
https://ir.library.oregonstate.edu/concern/articles/2j62s583t

Descriptions

Attribute NameValues
Creator
Abstract
  • We developed, synthesized, and tested a multifunctional nanostructured lipid nanocarrier- based system (NLCS) for efficient delivery of an anticancer drug and siRNA directly into the lungs by inhalation. The system contains: (1) nanostructured lipid carriers (NLC); (2) anticancer drug (doxorubicin or paclitaxel); (3) siRNA targeted to MRP1 mRNA as a suppressor of pump drug resistance; (4) siRNA targeted to BCL2 mRNA as a suppressor of nonpump cellular resistance and (5) a modified synthetic analog of luteinizing hormone- releasing hormone (LHRH) as a targeting moiety specific to the receptors that are overexpressed in the plasma membrane of lung cancer cells. The NLCS was tested in vitro using human lung cancer cells and in vivo utilizing mouse orthotopic model of human lung cancer. After inhalation, the proposed NLCS effectively delivered its payload into lung cancer cells leaving healthy lung tissues intact and also significantly decreasing the exposure of healthy organs when compared with intravenous injection. The NLCS showed enhanced antitumor activity when compared with intravenous treatment. The data obtained demonstrated high efficiency of proposed NLCS for tumor-targeted local delivery by inhalation of anticancer drugs and mixture of siRNAs specifically to lung cancer cells and, as a result, efficient suppression of tumor growth and prevention of adverse side effects on healthy organs.
  • Keywords: orthotopic lung cancer model, drug resistance, inhalation, imaging, Nanostructured lipid carrier, luteinizing hormone-releasing hormone (LHRH)
Resource Type
DOI
Date Available
Date Issued
Citation
  • Oleh Taratula, Andriy Kuzmov, Milin Shah, Olga B. Garbuzenko, and Tamara Minko. 2013. Nanostructured Lipid Carriers as Multifunctional Nanomedicine Platform for Pulmonary Co-Delivery of Anticancer Drugs and siRNA, Journal of Controlled Release, 171(3): 349-357. doi:10.1016/j.jconrel.2013.04.018
Journal Title
Journal Volume
  • 171
Journal Issue/Number
  • 3
Academic Affiliation
Rights Statement
Funding Statement (additional comments about funding)
  • This work was supported in part by grants from National Cancer Institute (R01 CA111766 and CA138533), National Institute of Environmental Health Sciences (R25 ES020721), National Science Foundation (CBET 0933966), and Department of Defense (W81XWH-10- 1-0347).
Publisher
Peer Reviewed
Language
Replaces

Relationships

Parents:

This work has no parents.

Items